WealthPlan Investment Management LLC Purchases 13,529 Shares of Oscar Health, Inc. $OSCR

Key Points

• WealthPlan Investment Management LLC increased its stake in Oscar Health, Inc. by 69.3% during Q2, acquiring an additional 13,529 shares to hold a total of 33,053 shares worth approximately $709,000.
• Oscar Health reported a loss of ($0.89) earnings per share for the most recent quarter, slightly beating analyst estimates, while revenue was $2.86 billion, showing a 29% increase year-over-year.
• Insider Mario Schlosser sold 395,000 shares at a price of $18.43, reducing his ownership by 44.08%, highlighting significant changes in insider activity amidst fluctuating stock performance.

WealthPlan Investment Management LLC grew its position in Oscar Health, Inc. (NYSE:OSCR - Free Report) by 69.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,053 shares of the company's stock after purchasing an additional 13,529 shares during the period. WealthPlan Investment Management LLC's holdings in Oscar Health were worth $709,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of OSCR. Vanguard Group Inc. raised its holdings in Oscar Health by 3.7% during the first quarter. Vanguard Group Inc. now owns 19,698,442 shares of the company's stock worth $258,247,000 after acquiring an additional 700,469 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Oscar Health by 4.1% during the first quarter. T. Rowe Price Investment Management Inc. now owns 11,826,245 shares of the company's stock worth $155,043,000 after acquiring an additional 467,301 shares in the last quarter. Thrive Capital Management LLC raised its holdings in Oscar Health by 33.4% during the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company's stock worth $85,258,000 after acquiring an additional 1,588,395 shares in the last quarter. BIT Capital GmbH raised its holdings in Oscar Health by 1.1% during the first quarter. BIT Capital GmbH now owns 4,521,445 shares of the company's stock worth $59,276,000 after acquiring an additional 47,592 shares in the last quarter. Finally, Glynn Capital Management LLC raised its holdings in Oscar Health by 14.0% during the first quarter. Glynn Capital Management LLC now owns 3,115,217 shares of the company's stock worth $40,840,000 after acquiring an additional 381,980 shares in the last quarter. 75.70% of the stock is currently owned by institutional investors.

Oscar Health Trading Up 1.7%

Shares of OSCR stock opened at $21.03 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 0.26. The stock has a market cap of $5.44 billion, a P/E ratio of -25.96 and a beta of 1.89. The stock has a 50 day simple moving average of $18.29 and a 200 day simple moving average of $16.05. Oscar Health, Inc. has a 1 year low of $11.20 and a 1 year high of $23.80.

Oscar Health (NYSE:OSCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.01. Oscar Health had a negative return on equity of 13.78% and a negative net margin of 1.50%.The business had revenue of $2.86 billion during the quarter, compared to analysts' expectations of $2.88 billion. During the same period in the previous year, the company posted $0.20 earnings per share. The firm's revenue for the quarter was up 29.0% compared to the same quarter last year. On average, research analysts predict that Oscar Health, Inc. will post 0.69 earnings per share for the current fiscal year.

Insider Activity at Oscar Health

In other news, insider Mario Schlosser sold 395,000 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $18.43, for a total value of $7,279,850.00. Following the completion of the transaction, the insider directly owned 501,148 shares in the company, valued at approximately $9,236,157.64. This represents a 44.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 24.39% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on OSCR shares. Wall Street Zen downgraded Oscar Health from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Robert W. Baird reissued a "neutral" rating and set a $14.00 price target (down previously from $28.00) on shares of Oscar Health in a research report on Friday, July 25th. Wells Fargo & Company boosted their price target on Oscar Health from $10.00 to $14.00 and gave the stock an "underweight" rating in a research report on Tuesday, October 7th. Zacks Research raised Oscar Health from a "strong sell" rating to a "hold" rating in a research report on Monday. Finally, UBS Group reissued a "sell" rating and set a $11.00 price target (down previously from $15.00) on shares of Oscar Health in a research report on Tuesday, July 15th. Six investment analysts have rated the stock with a Hold rating and six have issued a Sell rating to the company's stock. According to data from MarketBeat, Oscar Health presently has an average rating of "Reduce" and a consensus price target of $13.19.

About Oscar Health

Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.